Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Recruiting · NCT06885853 · Observational (researchers observe without assigning treatment) · Lead sponsor: Assistance Publique - Hôpitaux de Paris
View the official record on ClinicalTrials.gov →What this trial is about
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Men aged over 18 years
- Have received two doses of MVA-BN vaccine as an initial schedule
- Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
- Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
- Covered by social security (excluding AME)
Exclusion criteria
- History of mpox (virologically confirmed)
- Be under guardianship or curatorship
- Be subject to a judicial protection measure
- Have a contraindication to vaccination against mpox
Where it is running
1 location listed.
- CIC 1417Cochin-Pasteur - Paris, Paris, France